156 results about "Antigenic protein" patented technology

The invention discloses chicken infectious anemia virus-like particles as well as a preparation method and application thereof. The invention discloses a virus-like particle vaccine for preventing chicken infectious anemia. The virus-like particle vaccine comprises VP1 and VP2 proteins of chicken infectious anemia viruses. Chicken infectious anemia VP1 and VP2 proteins are expressed by using a baculovirus expression system, immunoblotting shows that the two proteins are successfully expressed in sf9 cells, electron microscope observation finds that the expressed proteins can be autonomously assembled into complete chicken infectious anemia virus-like particles, and the chicken infectious anemia virus-like particles have a space structure similar to that of an original virus and can be used for preparing chicken infectious anemia virus-like particles. Meanwhile, the virus-like particles have the advantages of high titer, high safety, capability of stimulating humoral immunity and cellular immunity and the like. The preparation method disclosed by the invention is simple, can be used for preparing the antigen protein of the chicken infectious anemia virus on a large scale, is high in expression quantity and short in time consumption, greatly reduces the production cost, and is suitable for large-scale production.

The invention discloses a swine fever and porcine parvovirus bivalent subunit vaccine and a preparation method thereof. The vaccine comprises a first recombinant protein encoded by a first gene, a second recombinant protein encoded by a second gene and a pharmaceutically acceptable carrier. The first gene has a sequence as shown in SEQ ID NO: 1 or an increased or reduced sequence thereof. And the second gene has a sequence as shown in SEQ ID NO: 2 or an increased or reduced sequence thereof. An antigen E2 protein of a hog cholera virus (CSFV) and a VP2 protein of a porcine parvovirus (PPV) are taken as double targets, a recombinant SC-E2 protein with a SpyCatcher tag and a recombinant ST-VP2 protein with a SpyTag tag are respectively expressed in insect cells through a recombinant baculovirus vector, double-antigen covalent assembly is realized in vitro, and the constructed bivalent subunit vaccine can be used for simultaneously preventing and controlling two epidemic diseases and has a good application prospect. And the vaccine has the advantages of high safety, strong immunogenicity, high prevention and control efficiency, easiness in large-scale production and the like.

This invention relates to compositions (e.g. immunogenic compositions) which can be used to immunise against C. acnes. The compositions comprise C. acnes antigens and antigen combinations, used in the form of nucleic acids (e.g. mRNAs) encoding antigenic proteins or in the form of recombinant protein antigens.

The invention relates to a QS-21 loaded nano adjuvant as well as a preparation method and application thereof. According to the nano adjuvant, the biodegradable polymer, cholesterol and cationic lipid entrapped QS-21 are utilized to form solid lipid particles in an O / W mode, the solid lipid particles have good dispersity, the surfaces of the solid lipid particles are positively charged, and the solid lipid particles can adsorb negatively charged antigen protein to prepare a nano adjuvant vaccine. The cholesterol in the nano adjuvant vaccine can be combined with the QS-21, so that entrapment of the QS-21 can be better realized, the safety and the stability of the nano adjuvant vaccine are improved, and the nano adjuvant vaccine has a wide application prospect in prevention of virus infection.

The present invention relates to the field of vaccines, and in particular to a novel adjuvant polypeptide sequence and a use thereof. The adjuvant polypeptide sequence provided by the present invention comprises amino acid sequences of tetanus toxoid epitopes P2 and P16 and further comprises amino acid sequences of P30 and / or PX. The adjuvant polypeptide sequence aims to expand the coverage population of immune responses by increasing epitope diversity. In addition, the present invention uses an LNP (lipid nanoparticle) delivery system to introduce an mRNA encoding an adjuvant polypeptide and an initial antigen protein into a human body, thereby improving the immunostimulatory ability of the initial antigen. The adjuvant polypeptide sequence provided by the present invention and the initial antigen sequence are preferably fused, thereby simplifying the composition of mRNA in a nucleic acid vaccine and reducing the complexity of vaccine preparation.

This invention provides a kit for detecting anti-peroxidase-1-IgG antibodies, comprising the antigen protein peroxiredoxin-1 (peroxidase-1), a solid-phase carrier, labeled antibody, antigen dilution buffer, sample dilution buffer, antibody dilution buffer, substrate chromogenic agent, washing buffer, standards, positive control, and negative control. This kit utilizes an indirect reaction principle combined with magnetic microparticle chemiluminescence immunoassay to detect anti-peroxidase-1-IgG antibodies in the serum of the test sample. This invention is the first to identify autoantibodies against the target antigen peroxidase-1 in the serum of patients with autoimmune nephrotic syndrome. The provided kit provides a basis for domestic and international research on the molecular mechanisms and clinical diagnosis and treatment of autoimmune nephrotic syndrome related to peroxidase-1 and peroxidase-1-IgG autoantibodies.

There is a modified coronavirus spike antigen protein and uses therefor. The spike antigen protein of coronavirus exhibits suppression of cell membrane fusion ability and improves safety by modifying two protein cleavage sites present in the coronavirus spike protein. In addition, inoculation with a vaccine having the antigen protein induces production of a large number of neutralizing antibodies to inhibit invasion of coronavirus into cells, thereby suppressing viral proliferation.

The invention discloses a blocking agent for cell immunofluorescence detection by a slide method and a use method of the blocking agent. The blocking agent is a homologous no-load cell lysis solution without transfection plasmids, and the protein concentration is greater than or equal to 30mg / mL. The blocking agent is completely the same as cell cytoplasm and cell membrane components of cells to be detected except for plasmids-expressed antigens, when in use, the blocking agent is pre-mixed with a blood cleaning sample in advance, interfering antibodies except target antibodies in serum can be purified, and meanwhile, due to the fact that no antigen protein expressed after plasmid transfection exists, the blocking agent can be used for detecting the cells to be detected. And the protein concentration is equivalent to the globulin concentration in serum, so that the target antibody cannot be lost in the serum, and the slide method CBA detection sensitivity can be greatly improved.

This invention belongs to the field of biotechnology and relates to a specific monoclonal antibody against porcine circovirus type 2 (PCV2) Cap protein and its applications. The CDR of the heavy chain variable region of the monoclonal antibody includes CDR1, CDR2, and CDR3 as shown in SEQ ID No. 1, SEQ ID No. 2, and SEQ ID No. 3, respectively; the CDR of the light chain variable region of the monoclonal antibody includes CDR1, CDR2, and CDR3 as shown in SEQ ID No. 4, SEQ ID No. 5, and SEQ ID No. 6, respectively. A sandwich ELISA method for protein content determination has been established, which is simple to operate, has good sensitivity and specificity, is widely applicable, and can perform high-throughput determination of multiple samples to detect the content of Cap protein, an effective antigen of various types of PCV2 vaccines, thus shortening the vaccine testing time.

The invention discloses an African swine fever mRNA vaccine composition capable of synergistically activating and enhancing humoral immunity and cellular immunity and application of the African swine fever mRNA vaccine composition, and belongs to the technical field of biological medicines. Specifically, a plurality of key antigen proteins of the African swine fever virus are used as target spots and are connected in series through connexons to form single-chain mRNA, so that multiple immunogens can be translated from the same transcript, and multiple antibodies are induced to be generated at the same time; a conservative recombinant T cell immunogen capable of activating cellular immune response is introduced, so that the cellular immune response can be enhanced, the ADE risk can be reduced, and the cross protection capability can also be improved; in addition, a molecular adjuvant IL-12 is added into the mRNA vaccine to enhance the immune response of the African swine fever vaccine, so that stronger immune protection efficacy is induced.

Disclosed herein are vaccine compositions, in particular, polyvalent icosahedral compositions for antigen presentation. The disclosed compositions may contain an S particle made up of recombinant fusion proteins. The recombinant fusion proteins may include a norovirus (NoV) S domain protein, a linker protein domain operatively connected to the norovirus S domain protein, and an antigen protein domain operatively connected to said linker.

This invention provides a specific detection method for *Daphnia magna* in nearshore marine aquatic ecosystem assessment. Based on obtaining the species-specific antigenic protein and key immunogenic peptides of *Daphnia magna*, a highly specific monoclonal antibody was successfully prepared and purified, and a colloidal gold side-flow chromatography rapid detection test strip was prepared using this antibody. The amino acid sequence of the antigenic protein is SEQ ID NO:1 or SEQ ID NO:2. This invention, by screening for the *Daphnia magna* species-specific antigen and its corresponding monoclonal antibody, combined with paired antibodies prepared from the full-length protein, and using them to develop a colloidal gold rapid immunoassay product, achieves for the first time high-throughput, rapid on-site screening of this species, significantly improving the efficiency and accuracy of marine ecological monitoring, ship ballast organism inspection, and aquaculture environmental assessment.

The invention discloses a bivalent subunit vaccine for preventing infection of haemophilus parasuis and porcine circovirus type 2. A core antigen combination of the vaccine comprises at least one antigen protein from haemophilus parasuis, and the antigen protein is selected from Ferrin, OppA and Hem-SAP and is combined with a porcine circovirus type 2 Cap protein. Wherein the NCBI (National Center of Biotechnology Information) login number of the Ferrin, the NCBI login number of the OppA and the NCBI login number of the Hem-SAP are WP160414389.1, ACL32731.1 and WP035493594.1 respectively. The antigen protein is subjected to codon optimization, is expressed and purified through a prokaryotic expression system, and is emulsified with ISA201 or a Freund's adjuvant to prepare the vaccine. Animal experiments prove that the vaccine can excite high-level antigen specificity IgG, cell factors IFN-gamma and white IL-4 in an immune animal body, namely, specific Th1 and Th2 type immune responses are generated. The vaccine can generate an immune protection rate of up to 80% when attacked by a serum type 5 haemophilus parasuis virulent strain, and generates an effective antibody response to the porcine circovirus type 2. The vaccine provided by the invention has the advantages of definite components, good safety and strong immune protection force.

Provided herein are RNA molecules encoding viral replication proteins and antigenic proteins or fragments thereof. Also provided herein are compositions that include RNA molecules encoding viral replication proteins and antigenic proteins or fragments thereof, and lipids. RNA molecules and compositions including them are useful for inducing immune responses.

This invention belongs to the field of biotechnology and discloses a dry film stabilizer, cytoplasmic antigen dry films, their preparation methods, and applications. The dry film stabilizer includes polyethylene glycol, trehalose, BSA, melatonin, and Tween-20. Cytoplasmic antigen dry films are prepared using this stabilizer and applied in CBA detection. This dry film stabilizer has good permeability, penetrating the cell membrane to enter the cell interior, providing protection both inside and outside the cell. It also possesses moisturizing and antioxidant properties, preventing cell deformation and shedding of the cell fixation layer, effectively maintaining the stability and reliability of intracellular antigen proteins. The prepared cytoplasmic antigen dry films can be stored long-term without damaging the antigenicity of cytoplasmic signal indicators. When detecting positive samples, strong and numerous green filamentous fluorescence signals are observed in the cytoplasm, with consistent green and red fluorescence intensities. Software synthesis reveals co-localization of green and red antigen fluorescence.

The present disclosure provides a type A foot-and-mouth disease virus-like particle antigen assembled by VP2, VP3 and VP1 antigen proteins of an epidemic strain of type A foot-and-mouth disease virus. The type A foot-and-mouth disease virus VP2 antigen protein is encoded by a nucleotide sequence shown in SEQ ID No. 1 or its degenerate sequence, the type A foot-and-mouth disease virus VP3 antigen protein is encoded by a nucleotide sequence shown in SEQ ID No. 2 or its degenerate sequence, and the type A foot-and-mouth disease virus VP1 antigen protein is encoded by a nucleotide sequence shown in SEQ ID No. 3 or its degenerate sequence.

A method for inducing an immune response in an individual to treat or prevent a disease or condition is provided, the method comprising administering a vaccine comprising lipid nanoparticles encapsulating nucleic acids encoding antigen proteins, peptides, or fragments thereof, a neutral lipid content of 30% to 70% molar ratio, sterols or derivatives thereof, and 5 to 50% molar ratio of ionizable cationic amino lipids, and a hydrophilic polymer-lipid conjugate present at a lipid content of 0% to 5% molar ratio, wherein administration of the lipid nanoparticles results in an immune response in an individual against the antigen protein, peptide, or fragment thereof expressed by mRNA, wherein each % molar ratio of lipid content relative to the total lipid content of the lipid nanoparticles is measured. This disclosure also provides vaccine compositions and the use of such compositions in inducing an immune response in an individual.

The present application relates to a kind of cat rhinotracheitis, feline calicivirus disease, cat pancytopenia triple subunit vaccine, preparation method and its application.The present application is expressed antigen protein using CHO cell strain, and synergistic effect is combined molecular adjuvant (IL-2, GM-CSF, CpG) with MF59 nanoemulsion, molecular adjuvant composition is adsorbed on the surface of MF59 nanoemulsion, then embedded in polylactic acid-glycolic acid copolymer microsphere, mixed with triple subunit protein to form vaccine preparation.The vaccine prepared in the present application can stimulate humoral immunity and cellular immunity simultaneously by subcutaneous or intramuscular injection, significantly improve antibody titer and attack protection rate, prolong immune protection period, and reduce injection site adverse reactions.The synergistic effect of protein and molecular adjuvant and MF59 makes the vaccine superior to traditional subunit vaccine in safety, stability and immunological efficacy, and is suitable for high-efficiency prevention of three viral infectious diseases in feline.

A method of diagnosing systemic lupus erythematosus using an antigen protein that binds specifically to an SMYD3 autoantibody present in body fluid of a patient with systemic lupus erythematosus. The diagnostic method uses a non-invasive biological sample such as blood, and thus may diagnose systemic lupus erythematosus very conveniently without burdening the patient, unlike conventional methods. In addition, the method has high specificity and sensitivity, and thus may be effectively used for early diagnosis of systemic lupus erythematosus.

The object of the present invention is to provide an active ingredient for a systemically administered mRNA pharmaceutical that expresses an antibody specific to the V antigen protein or its homologous protein of Gram-negative bacteria, and a systemically administered mRNA pharmaceutical using the same. [Solution] mRNA containing an antibody coding region encoding a specific scFv antibody against the V antigen protein or its homologous protein of pathogenic Gram-negative bacteria is useful as an active ingredient in mRNA pharmaceuticals for systemic administration.

The invention belongs to the technical field of biological medicines, and particularly relates to an anti-CD22 nano antibody as well as a preparation method and application thereof. The anti-CD22 nano antibody comprises a framework region and a complementarity determining region, wherein the complementarity determining region comprises CDR1 (SEQ ID NO: 1), CDR2 (SEQ ID NO: 2) and CDR3 (SEQ ID NO: 3). The preparation method comprises the following steps: immunizing alpaca by using Human CD22 / His protein, extracting RNA (Ribonucleic Acid) from PBMC (Peripheral Blood Mononuclear Cell) and reversely transcribing into cDNA (Complementary Deoxyribose Nucleic Acid), constructing a phage display library, then performing CD22 antigen protein elutriation to obtain positive clone, and after sequencing analysis, expressing the antibody by using a mammalian cell expression system. The optimized phage display technology is adopted, the screening period is short, and the obtained nano antibody is small in molecular weight, stable in structure and high in affinity to CD22. The antibody can be efficiently expressed through mammalian cells, and natural modification activity is reserved.

Levels of expression of antibiotic resistance genes are increased up to six-fold by inserting a proteasome-targeting tag into transgenes expressed in eukaryotic cells. Various selectable marker proteins are combined with different destabilization domains, leading to up to 70% increase in transgene expression. The increase in expression varies highly depending on the engineered construct and the lines cells used. Increase in expression drives exosome loading of cargo proteins in some aspects. By increasing expression and by editing trafficking signals of cargo proteins, proteins that normally locate to the ER can be trafficked to exosomes. This disclosure discloses efficient exosome delivery of a wide variety of engineered proteins, including modified antigen proteins of SARS-CoV-2 and influenza, and other proteins such as a modified alpha galactosidase A, an extracellular domain of vascular endothelial growth factor fused to a constant region of a human immunoglobulin heavy chain, and modified trastuzumab heavy and light chains.

The application provides a recombinant antigen protein p22 of an African swine fever virus, a monoclonal antibody and application. The application provides a recombinant antigen protein of an African swine fever virus. The application provides an antibody or antigen binding fragment thereof of the recombinant antigen protein of the African swine fever virus. The application also provides a hybridoma cell. The application also provides a rapid detection test paper card of the African swine fever antibody. The recombinant antigen protein of the African swine fever virus provided by the application has higher affinity to the African swine fever antibody, higher specificity and better stability, and can be used for rapid and accurate detection of the African swine fever virus.

The present application relates to an isolated antigen binding protein capable of binding to ROR1 (Receptor Tyrosine Kinase Orphan Receptor 1), said isolated antigen protein comprising CDR1, CDR2 and CDR3. The present application also provides a method for preparing said isolated antigen binding protein and uses thereof.

This invention relates to a fusion protein, immunogenic composition, and recombinant vaccine for the prevention of Escherichia coli infection. The invention provides a novel target, PstS, for Escherichia coli vaccine design. Starting from the tertiary structure of PstS and YidR proteins, and combining immunoepitaxes, stable domains of PstS and YidR proteins and their variants are ultimately screened, leading to the construction of a fusion protein. Both the PstS monoantigen protein molecule and the PstS-YidR fusion protein molecule of this invention exhibit good immunogenicity, can reduce tissue lesions caused by Escherichia coli infection, and demonstrate high efficacy in preventing Escherichia coli infection, showing broad application prospects.

The invention relates to a preparation method and application of an oligopeptide / polypeptide substitution antibody, and belongs to the technical field of antibody preparation. In order to solve the problems that an existing antibody preparation method is high in complexity, poor in stability and limited in platform applicability, the invention provides a preparation method of an oligopeptide / polypeptide substitution antibody, firstly, a random DNA sequence is synthesized and cloned to a two-hybrid system prey vector to construct a peptide library, an antigen protein is cloned to a two-hybrid system bait vector, and then the oligopeptide / polypeptide substitution antibody is obtained. Screening an antigen interaction peptide sequence through bait and prey library two-hybrid interaction, and performing prokaryotic expression purification or direct artificial synthesis on the antigen interaction peptide sequence to obtain a short peptide / polypeptide interacting with an antigen protein as an antibody substitute. According to the invention, ethical dispute and batch difference of animal immunity in traditional antibody preparation are avoided, period is shortened, cost is reduced, non-specific binding is less, sensitivity is greatly improved, plant endogenous non-tag protein can be specifically recognized, and the method is widely applicable to scenes of antibody substitution.

The present invention relates to a conjugate comprising an mRNA of an antigen protein and an mRNA encoding a carrier protein linked to the 5'terminal and the 3 'terminal of the mRNA of the antigen protein, and an vaccination composition and / or a vaccine composition comprising the conjugate, the present invention having an effect of stably increasing the expression of an antigen protein.

This invention provides a broad-spectrum mRNA vaccine for the prevention of feline infectious peritonitis (FIP) and its preparation method. The vaccine comprises mRNA molecule 1 and mRNA molecule 2. mRNA molecule 1 contains an LS-FIPV-I MEV-N-M antigen protein coding sequence composed of a self-assembled LS nanoparticle fusion sequence based on a tandem neutralizing epitope of the FIPV type I S protein and a T-cell epitope, as well as antigen-coding sequences of the N and M proteins. mRNA molecule 2 contains an antigen protein coding sequence of an LS nanoparticle structure self-assembled from the FIPV type II S protein receptor domain RBD. This invention, through the combination of two mRNA molecules, can achieve broad-spectrum protection against both FIPV types I and II while mitigating the risk of adverse drug reaction (ADE).

The invention discloses an HCV recombinant fusion antigen protein which comprises a Core antigen epitope, an NS3 antigen epitope region and an NS5A antigen epitope of HCV which are connected in series, the amino acid sequence of the Core antigen epitope is as shown in SEQ ID NO: 1, the amino acid sequence of the NS3 antigen epitope is as shown in SEQ ID NO: 2, and the amino acid sequence of the NS5A antigen epitope is as shown in SEQ ID NO: 3. The HCV recombinant fusion antigen protein obtained by the invention has relatively high detection rate and specificity.

The invention discloses a nucleic acid molecule which comprises an open reading frame for coding an EBV antigen, and the EBV antigen is a specific antigen which is contained in a diseased cell of an EBV related disease, is coded by an EBV virus genome and is in a cell and on a cell membrane; the EBV antigen comprises LMP1, LMP2A, LMP2B, EBNA-LP, EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, EBNA4, EBNA5, EBNA6, EBNA7 and EBNA8, as well as lipid nanoparticles containing nucleic acid molecules, a pharmaceutical composition and application thereof, and belongs to the technical field of biology. The nucleic acid molecule, the mRNA, the composition containing the nucleic acid molecule, and the lipid nanoparticles can significantly increase the number of tumor specific immune cells, effectively activate immune response, and significantly inhibit tumor growth, and have significant anti-tumor activity for nasopharynx cancer and lymphoma.